GALNT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7980209	1.00	1/20
SCHEMBL29370098	1.00	1/20
SCHEMBL26768213	0.79	1/20
SCHEMBL7987277	0.69	1/20
SCHEMBL2357304	0.68	1/20
SCHEMBL29466713	0.68	1/20
SCHEMBL29827270	0.68	1/20
SCHEMBL17949557	0.66	1/20
SCHEMBL7984298	0.66	1/20
SCHEMBL9748319	0.61	1/20
SCHEMBL21517158	0.61	1/20
SCHEMBL3874869	0.61	1/20
SCHEMBL15285080	0.61	1/20
SCHEMBL31414410	0.61	1/20
SCHEMBL7330918	0.60	1/20
SCHEMBL22431062	0.59	1/20
SCHEMBL1444851	0.58	1/20
SCHEMBL30451609	0.58	1/20
SCHEMBL5351976	0.58	1/20
SCHEMBL7227954	0.57	1/20

Clinical trials — most relevant to GALNT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC	nan	RECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
The Natural History of Sialidosis Type I	nan	RECRUITING
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Intervention and Outcomes in Duarte Galactosemia	nan	COMPLETED
Italian Anderson Fabry Disease Cardiovascular Registry	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GALNT1 binder may also engage these)

Protein	Name	Similarity
Q29121	—	1.000	Q29121 →
O08912	—	1.000	O08912 →
Q8CF93	—	1.000	Q8CF93 →
Q07537	—	1.000	Q07537 →
Q10473	—	1.000	Q10473 →
GALNT13	Polypeptide N-acetylgalactosaminyltransferase 13	1.000	landscape →
Q6UE39	—	1.000	Q6UE39 →
Q8MV48	—	0.999	Q8MV48 →
Q8BVG5	—	0.999	Q8BVG5 →
Q49A17	—	0.998	Q49A17 →
S5S833	—	0.998	S5S833 →
Q6WV17	—	0.998	Q6WV17 →
GALNT10	Polypeptide N-acetylgalactosaminyltransferase 10	0.998	landscape →
Q6PB93	—	0.997	Q6PB93 →
GALNT14	Polypeptide N-acetylgalactosaminyltransferase 14	0.996	landscape →
Q925R7	—	0.996	Q925R7 →
P70419	—	0.995	P70419 →
GALNT3	Polypeptide N-acetylgalactosaminyltransferase 3	0.994	landscape →
GALNT2	Polypeptide N-acetylgalactosaminyltransferase 2	0.994	landscape →
Q8C7U7	—	0.994	Q8C7U7 →
Q6P6V1	—	0.994	Q6P6V1 →
Q5EA41	—	0.994	Q5EA41 →
Q8NCW6	—	0.994	Q8NCW6 →
Q921L8	—	0.994	Q921L8 →
Q8I136	—	0.994	Q8I136 →
Q6WV19	—	0.994	Q6WV19 →
Q8IXK2	—	0.994	Q8IXK2 →
Q6WV16	—	0.994	Q6WV16 →
O61397	—	0.994	O61397 →
Q6DJR8	—	0.994	Q6DJR8 →